Drug Trial Radar · NCT05774184
A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
86
Actual
Start
Jun 1, 2023
Primary completion
Jun 4, 2025
Study completion Jan 23, 2026
Sponsor
- Lead sponsor
- Celldex TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adult Eosinophilic Esophagitis patients.
Conditions
- Eosinophilic Esophagitis
Interventions
barzolvolimabBiological
subcutaneous administration
Matching PlaceboDrug
subcutaneous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute change from baseline to Week 12 in peak intraepithelial mast cell (PMC) count (PMC/hpf).Time frame: From baseline to Visit 6 (Week 12)
Locations
45 sites in 8 countries. Site status is shown where the registry gives one.
AllerVie Clinical Research
Birmingham, Alabama
One of a Kind Clinical Research Center
Scottsdale, Arizona
GI Alliance- Arizona Digestive Health- Sun City
Sun City, Arizona
Del Sol Research Management, LLC
Tucson, Arizona
GW Research Inc.
Chula Vista, California
Connecticut Clinical Research Institute, LLC
Bristol, Connecticut
ENCORE Borland Groover Clinical Research
Jacksonville, Florida
Gastroenterology of Greater Orlando
Orange City, Florida
Treasure Valley Medical Research
Boise, Idaho
Northwestern University
Chicago, Illinois
University of Iowa
Iowa City, Iowa
University of Kansas Medical Center (KUMC)
Kansas City, Kansas
Tandem Clinical Research
Marrero, Louisiana
Boston Specialists - Boston Food Allergy Center
Boston, Massachusetts
NYU Langone Health
New York, New York
University of North Carolina (UNC) Hospitals
Chapel Hill, North Carolina
Duke University Medical Center
Durham, North Carolina
The Clinical Trials Network, LLC
Willoughby, Ohio
The Pennsylvania State University (Penn State) Milton S. Hershey Medical Center
Hershey, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania
Vanderbilt University Medical Center-GI Clinical Research Program
Nashville, Tennessee
Advanced Research Institute - Ogden
Ogden, Utah
Care Access Research
Salt Lake City, Utah
University of Utah
Salt Lake City, Utah
St Vincent's Hospital Melbourne
Melbourne, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
University of Calgary
Calgary, Alberta, Canada
PerCuro Clinical Research Ltd.
Victoria, British Columbia, Canada
Universitaetsklinikum Augsburg
Augsburg, Germany
Klinikum Region Hannover GmbH Burgwedel
Hanover, Germany
Universitaetsklinikum Magdeburg A.oe.R.
Magdeburg, Germany
IRCCS Ospedale San Raffaele
Milan, Italy
Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Rome, Italy
Istituto Clinico Humanitas
Rozzano, Italy
Azienda Ospedaliera Universitaria OO.RR. San Giovanni di Dio Ruggi d'Aragona-Plesso "Ruggi"
Salerno, Italy
Azienda Ospedaliera - Universitaria Integrata di Verona - Ospedale Borgo Roma
Verona, Italy
Centrum Medyczne Med-Gastr Sp. z o.o.
Lodz, Poland
WIP Warsaw IBD Point Profesor Kierkus
Warsaw, Poland
Wojskowy Instytut Medyczny - Panstwowy Instytut Badawczy, Klinika Gastroenterologii i Chorob
Warsaw, Poland
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.